RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 08/09/13 -- Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex will focus its remaining resources on the development of Sodium Thiosulfate (STS), a chemoprotectant for the prevention of hearing loss in pediatric oncology patients undergoing platinum-based chemotherapy. The Company plans to seek a partnership for eniluracil (EU) and at this time will not undertake additional clinical work.
"We think that STS has the potential to fill an important unmet medical need in pediatric oncology," stated Mr. Rosty Raykov, Chief Executive Officer of Adherex, "Platinum based drugs are broadly used in children undergoing chemotherapy where they are known to produce profound and irreversible hearing loss. Currently, there is no effective means to prevent this debilitating side effect. Because the two Phase III clinical trials with STS are conducted and supported by cooperative oncology groups, we expect to advance this product to market with modest additional expenditure."
" We encourage our shareholders to visit our website and review our updated corporate presentation, which has additional details on our plans for STS," added Mr. Raykov.
Sodium Thiosulfate (STS)
STS is a chemoprotectant being developed by Adherex to reduce or prevent hearing loss in oncology patients resulting from treatment with platinum-based chemotherapy drugs. The initial focus is on the pediatric market. Hearing loss following cisplatin exposure affects approximately 2,000 children in the US every year. STS has received Orphan Drug Designation in the United States for the prevention of platinum-induced ototoxicity in pediatric patients. In addition, Adherex has licensed intellectual property rights for the use of STS as a chemoprotectant from Oregon Health & Science University.
STS is a water-soluble thiol compound and acts as a chemical reducing agent. It is FDA approved for the treatment of cyanide poisoning and has been used in oncology to prevent cisplatin nephrotoxicity. It is thought that hearing loss caused by platinum compounds result from the deposition of protein-bound platinum in the cochlea and STS binds platinum/protein complexes thereby potentially minimizing their toxicity. At a bolus dose of 20 g/m2 over 15 minutes, STS has sufficient high plasma concentrations to rapidly, covalently bind to any residual extracellular cisplatin and thereby possibly prevent ototoxicity. Because STS is to be administered six hours after cisplatin, antitumor efficacy of cisplatin should not be compromised.
STS is being investigated by cooperative groups in two Phase III clinical studies to evaluate the reduction of ototoxicity and impact on survival:
Study ACCL0431: "A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children", conducted by the Children's Oncology Group (COG), finished enrollment of 135 patients in 1Q 2012. These patients had been previously diagnosed with one of five rare childhood cancers typically treated with intensive cisplatin therapy, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. Final data from the study is expected to be released by COG in the third quarter of 2013.
Most Popular Stories
- 15 Myths That Could Ruin Your Hispanic Ad Campaign
- Bitcoin Clones Lurch Onto Financial Scene
- General Motors Names Mary Barra as First Female CEO
- AIG to Create 230 Jobs in Charlotte
- Clinton to Keynote Annual Simmons Leadership Conference
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia
- Californians Want to Legalize Marijuana
- Scripps Shares Rise on Reported Bid Talks
- Russia Says Nyet to Canada North Pole Claim
- Budget Deal Sets Off Grumbles in Both Houses